Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer.

Trial Profile

Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Early breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Oct 2017 Results (n=213) of study developing and validating a tool to predict response by assessing association between pathological response and early changes in tumor infiltrating lymphocytes using patient data from NCT01973660 and NCT00524303 trials published in the Annals of Oncology
    • 07 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top